Abstract:Objective To investigate the efficacy and safety of the cetuximab combined with chemotherapy for patients with metastasis from colorectal cancer whose K-Ras status were wild type and explore the factors that may affect the efficacy and prognosis. Methods Retrospectively collected the clinical data of 90 patients with metastasis from colorectal cancer whose K-Ras status were wild type. Cetuximab 400mg/m2 was intravenously given at first dose and maintenance at 250mg/m2 every week or 500mg/m2 every two weeks. Combined chemotherapy regimen included, irinotecan-based chemotherapy(FOLFIRI or XELIRI or irinotecan monotherapy), oxaliplatin-based chemotherapy( FOLFOX or XELOX) ,other regimens, such as 5-FU/leucovorin or capecitabine monotherapy. The ef-ficacy and safety of each line of chemotherapy was summarized and assessed, and the relationship between clinicopathology features, treatment characteristics and efficacy, explore the factors associated with prognosis were analyzed retrospectively. Results The median duration treatment of cetuximab was 16 weeks( 6-44 weeks) . And in all patients the objective response rate( ORR) was 45?6%,and the disease control rate( DCR) was 87?8%. The DCR in first line treatment was 51?6% better than in second line, whose was 40?0%, and the DCR in third line was 18?2%. The age, location of primary tumor, treatment time of cetuximab might affect the efficacy fo cetux- imab plus chemotherapy. In the 90 patients, recurrent metastases were occurred in 82 cases( 91?1%) and death in 60 cases( 66?7%) . The median PFS( mPFS) was 7?8 months and median OS( mOS) was 22?5 months. In the first line treatment of cetuximab plus chemo-therapy, mPFS was 9?1 months and mOS was 27?6 months. In second line treatment mPFS was 7?7 months and mOS was 14?5 month. in third line mPFS was 2?9 months and mOS was 6?7 months. Univariate survival analysis showed that the location of primary tumor, early tumor response and treatment time of cetuximab were related to PFS and OS of the patients, and the metastasis scope was related to the OS of patients. Using the Cox multivariate hazards model to analysis the clinicopathological factors, which showed that the loca-tion of primary tumor and early tumor response were the independent risk factors affecting the PFS of patients, the metastasis scope was the independent risk factor affecting the OS of patients. The most common adverse reaction related to cetuximab is acne-like rash, the side effects associated with chemotherapy mainly were diarrhea, nausea, vomiting, bone marrow suppression. After symptomatic treat-ment, patients can tolerate. Conclusion Cetuximab combined chemotherapy in each line treatment of patients with metastases from colorectal cancer can get great efficacy, and the adverse reactions can be tolerated. The location of primary tumor might be the predic-tors of the efficacy, and it is also associated with the prognosis of the patients. As ETS Shows that early tumor response could be one of the outcome indicators of mCRC.

Maintenance Treatment with Capecitabine Plus Cetuximab (CET) for Patients with RAS Wild-Type (wt) Advanced Colorectal Cancer (CRC): A Multi-Center, Phase II Clinical Trial.

China Special Issue on Gastrointestinal Tumors‐cetuximab Retreatment Plus Camrelizumab and Liposomal Irinotecan in Patients with RAS Wild‐type Metastatic Colorectal Cancer: Cohort B of the Phase II CRACK Study

Cetuximab retreatment plus camrelizumab and liposomal irinotecan in patients with RAS wild-type metastatic colorectal cancer: Cohort B of the phase II CRACK study

Effect of Reduced-Dose Capecitabine Plus Cetuximab As Maintenance Therapy for RAS Wild-Type Metastatic Colorectal Cancer

A Real-World Retrospective Study to Evaluate the Reliability of Cetuximab Plus Capecitabine Versus Capecitabine As Maintenance Therapy in Patients with RAS and BRAF Wild-Type Metastatic Colorectal Cancer.

A Study of Gene Variation in All-RAS Wild-Type Metastatic Colorectal Cancer and Its Correlation with Cetuximab.

A Retrospective Exploration of Targeted Maintenance Therapy in Advanced Colorectal Cancer: Based on the Background of Chinese Patient Assistance Program.

511Tip A Phase III, Multicenter, Open-Label, Randomized Study to Assess the Efficacy and Safety of Cetuximab Plus Capecitabine Versus Cetuximab As Maintenance Treatment Following First-Line Induction Treatment with FOLFOX and Cetuximab in Chinese Patients with RAS and BRAF WT Mcrc

Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety

[Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].

Efficacy and Safety of Every-2-weeks Cetuximab Combined with FOLFOX or FOLFIRI As First-Line Therapy in Patients with KRAS Wild-Type Metastatic Colorectal Cancer (mcrc): an Asia-Pacific Nonrandomized Phase II Study (APEC).

A phase I/IIa study of cetuximab combined with fruquintinib in the previously treated RAS/BRAF wild-type metastatic colorectal cancer: Results of the CEFRU study.

Rechallenge and Maintenance Therapy Using Cetuximab and Chemotherapy Administered to a Patient with Metastatic Colorectal Cancer.

Survival Analysis of Cetuximab Combined with Chemotherapy for Advanced Colorectal Cancer and Effect of KRAS on Treatment

Capecitabine Maintenance Therapy after Adjuvant Chemotherapy of Folfox (or Xelox) in Patients with Stage Iiic or R0 Resected Stage Iv Colorectal Cancer (camco Study).

Continuing Cetuximab vs Bevacizumab plus chemotherapy after first progression in wild-type KRAS , NRAS and BRAF V600E metastatic colorectal cancer: a randomized phase II trial

Capecitabine maintenance therapy after first-line chemotherapy in patients with metastatic colorectal cancer

A Study of Capecitabine Metronomic Chemotherapy is Non-Inferior to Conventional Chemotherapy As Maintenance Strategy in Responders after Induction Therapy in Metastatic Colorectal Cancer

Efficacy analysis of cetuximab plus chemotherapy for K-Ras wild-type colorectal cancer with metastases

Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer

Quality of Life (qol) Analyses in Patients with RAS Wild-Type (wt) Metastatic Colorectal Cancer (mcrc) Treated with First-Line FOLFOX-4 ± Cetuximab in the Phase 3 TAILOR Trial